サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1651002

心不全治療薬の世界市場

Heart Failure Drugs

出版日
ページ情報
英文 179 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
心不全治療薬の世界市場
出版日: 2025年02月07日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 179 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

心不全治療薬の世界市場は2030年までに191億米ドルに達する見込み

2024年に95億米ドルと推定される心不全治療薬の世界市場は、2030年には191億米ドルに達し、分析期間2024-2030年のCAGRは12.4%で成長すると予測されます。

米国市場は24億米ドル、中国はCAGR16.3％で成長予測

米国の心不全治療薬市場は、2024年に24億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに46億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは16.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.6%と10.2%と予測されています。欧州では、ドイツがCAGR約9.6%で成長すると予測されています。

世界の心不全治療薬市場- 主要動向と促進要因のまとめ

なぜ心不全治療薬がこの広範な症状の管理に重要なのか？

心不全治療薬は、世界中で数百万人が罹患している心不全を管理する上で極めて重要な役割を果たしており、症状の軽減、生活の質の向上、生存期間の延長に役立っています。心不全は、心臓の血液を送り出す能力が低下した慢性疾患で、効果的に管理されなければ、重大な罹患率と死亡率につながります。心不全治療薬の第一の目標は、心臓への負担を軽減し、血流を改善し、病態の悪化を防ぐことです。β遮断薬、アンジオテンシン変換酵素（ACE）阻害薬、利尿薬などの薬剤は、血圧を下げ、心臓のリズムを整え、血行不良のためにたまりやすい余分な水分を排出することで、心不全を管理するために一般的に処方されます。これらの薬剤がないと、患者は体液貯留、疲労、息切れなどの合併症のリスクが高くなります。心不全が重症化すると、入院や突然死に至ることもあります。したがって、心不全治療薬の開発と最適化は、症状のコントロールだけでなく、入院を減らし、長期的な生存予後を改善するためにも不可欠です。

心不全治療薬の異なるクラスはどのように患者の転帰を改善するのか？

心不全治療の中心となる薬剤にはいくつかのクラスがあり、それぞれが疾患の異なる側面に対処しています。ACE阻害薬とアンジオテンシンII受容体拮抗薬（ARB）はしばしば第一選択薬です。これらは血管を弛緩させ、心臓の負担を減らすことで血圧を下げ、血流を改善します。β遮断薬も不可欠な薬剤クラス別であり、心拍数を減少させ、収縮力を低下させることで、心臓がより効率的に働き、時間をかけて負担から回復できるようにします。一般に水薬として知られる利尿薬は、余分な水分を体外に排出してむくみを改善し、肺にたまる水分を減らして呼吸を改善します。さらに、アンジオテンシン受容体-ネプリライシン阻害薬（ARNI）のような新しい薬剤クラス別は、心臓への負担を軽減し、症状の悪化を防ぐことによって心機能を改善するのに非常に効果的であることが分かってきました。サクビトリル/バルサルタンのようなこれらの薬剤は、臨床試験において生存率の有意な改善と入院の減少を示しています。もう一つの重要なクラスにはアルドステロン拮抗薬があり、これは過剰なアルドステロンの有害な作用を阻害します。このホルモンは体液貯留を促進し心機能を悪化させることによって心不全を悪化させる。心不全に関与するさまざまな経路を標的とすることで、これらの薬剤は相乗的に作用し、症状を軽減し、疾患の進行を遅らせ、患者の全体的な転帰を改善します。

心不全治療薬における最新の開発とイノベーションとは？

心不全治療の情勢は進化しており、より良い管理と転帰に希望を与えるいくつかの有望な開発があります。近年の最も重要な技術革新の1つは、ナトリウムグルコース共輸送体2（SGLT2）阻害薬の使用です。当初は2型糖尿病の治療薬として開発されたが、ダパグリフロジンやエンパグリフロジンなどのこれらの薬剤は、糖尿病のない心不全患者においても、入院や死亡のリスクを減少させるという素晴らしい結果を示しています。この薬剤クラス別は、腎臓が余分なブドウ糖とナトリウムを除去するのを助けることによって作用し、その結果、血液量と血圧が低下し、心臓の負担が軽減されます。さらに、将来の心不全治療の可能性として遺伝子治療が注目されています。研究者たちは、特定の遺伝子を修正することで、損傷した心臓組織を修復・再生し、単なる対症療法ではなく長期的な解決策を提供する方法を模索しています。健康な心臓組織の再生を促進することで、心臓の損傷を回復させる可能性のある新規の生物製剤や細胞ベースの治療法の開発も、革新的な分野です。これらの先進的な治療法の有効性を検証する臨床試験が進行中であり、今後数十年間の心不全治療において大きなブレークスルーとなる可能性があります。このような開発は、既存の薬剤製剤の継続的な改良とともに、心不全治療戦略を絶えず改良し、患者により個別化された効果的な選択肢を提供しています。

心不全治療薬市場の主な成長促進要因は？

心不全治療薬市場の成長は、医学の進歩、人口動態の変化、患者ニーズの変化に直接関連するいくつかの要因によってもたらされます。最も重要な要因の一つは、人口の高齢化と、心不全の主要な危険因子である高血圧、糖尿病、冠動脈疾患などの心血管疾患の罹患率の増加により、心不全の有病率が上昇していることです。世界人口の高齢化と慢性疾患の蔓延に伴い、効果的な心不全治療に対する需要は増加の一途をたどっています。また、創薬や製薬技術の進歩により、SGLT2阻害薬やARNIのような、より効果的な新薬が開発され、標準治療が変革され、心不全治療薬の市場も拡大しています。さらに、特に進行した心不全患者のQOL（生活の質）を向上させることに注目が集まっており、新しい薬物療法は病院での再入院を減らし、症状をより効果的に管理することを目指しています。もう一つの重要な推進力は、より優れた診断ツールとスクリーニングプログラムによって促進される心不全の認識と早期診断の増加であり、早期介入とより持続的な薬物使用につながります。さらに、製薬業界では、遺伝的要因、臨床的要因、ライフスタイル要因に基づいて個々の患者に合わせた治療を行う個別化医療へのシフトも市場を拡大しています。このような個別化アプローチにより、心不全のより効果的な管理が可能になり、革新的な標的治療薬への需要がさらに高まっています。最後に、官民両部門による研究開発への多額の投資により、新しい治療法の継続的なパイプラインが確保され、より効果的な新しいソリューションが市場に投入されるにつれて、心不全治療薬市場の成長に拍車がかかります。

セグメント

セグメント（心不全治療薬）

調査対象企業の例（全11件）

  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim（Canada）Ltd.
  • Bristol-Myers Squibb Company
  • CRC Health
  • Exelixis, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lunan Pharmaceuticals Co. Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Shanghai Haini Pharmaceutical Co., Ltd.
  • Shanghai Xudong Haipu Pharmaceutical Co., Ltd.
  • The National Council for Palliative Care
  • Valeant Pharmaceuticals International, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP11264

Global Heart Failure Drugs Market to Reach US$19.1 Billion by 2030

The global market for Heart Failure Drugs estimated at US$9.5 Billion in the year 2024, is expected to reach US$19.1 Billion by 2030, growing at a CAGR of 12.4% over the analysis period 2024-2030.

The U.S. Market is Estimated at US$2.4 Billion While China is Forecast to Grow at 16.3% CAGR

The Heart Failure Drugs market in the U.S. is estimated at US$2.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.6 Billion by the year 2030 trailing a CAGR of 16.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.6% and 10.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.6% CAGR.

Global Heart Failure Drugs Market - Key Trends and Drivers Summarized

Why Are Heart Failure Drugs Critical in Managing This Widespread Condition?

Heart failure drugs play a pivotal role in managing a condition that affects millions worldwide, helping to reduce symptoms, improve quality of life, and prolong survival. Heart failure, a chronic condition where the heart’s ability to pump blood is compromised, can lead to significant morbidity and mortality if not effectively managed. The primary goal of heart failure drugs is to alleviate the strain on the heart, improve blood flow, and prevent the worsening of the condition. Medications such as beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, and diuretics are commonly prescribed to manage heart failure by reducing blood pressure, regulating heart rhythms, and eliminating excess fluids that can build up due to poor circulation. Without these medications, patients face a higher risk of complications such as fluid retention, fatigue, and shortness of breath. In severe cases, unmanaged heart failure can result in hospitalizations or even sudden death. Therefore, the development and optimization of heart failure drugs are essential not only for symptom control but also for reducing hospital admissions and improving long-term survival outcomes.

How Do Different Classes of Heart Failure Drugs Work to Improve Patient Outcomes?

There are several classes of drugs that are central to heart failure management, each addressing different aspects of the disease. ACE inhibitors and angiotensin II receptor blockers (ARBs) are often first-line therapies. They work by relaxing blood vessels and reducing the workload on the heart, which lowers blood pressure and improves blood flow. Beta-blockers are another essential class of drugs that reduce heart rate and decrease the force of contraction, allowing the heart to work more efficiently and recover from strain over time. For patients who retain excess fluids, diuretics, commonly known as water pills, help to remove this excess fluid from the body, reducing swelling and improving breathing by lowering fluid buildup in the lungs. Additionally, newer drug classes like angiotensin receptor-neprilysin inhibitors (ARNIs) have emerged as highly effective in improving heart function by reducing strain on the heart and preventing worsening of symptoms. These drugs, like sacubitril/valsartan, have shown significant improvements in survival rates and reduced hospitalizations in clinical trials. Another important class includes aldosterone antagonists, which block the harmful effects of excess aldosterone—a hormone that can exacerbate heart failure by promoting fluid retention and worsening cardiac function. By targeting different pathways involved in heart failure, these medications work synergistically to reduce symptoms, slow disease progression, and improve overall outcomes for patients.

What Are the Latest Developments and Innovations in Heart Failure Drug Therapies?

The landscape of heart failure treatment is evolving, with several promising developments that offer hope for better management and outcomes. One of the most significant innovations in recent years is the use of sodium-glucose cotransporter-2 (SGLT2) inhibitors. Initially developed as a treatment for type 2 diabetes, these drugs, such as dapagliflozin and empagliflozin, have demonstrated impressive results in reducing the risk of hospitalization and death in heart failure patients, even those without diabetes. This class of drugs works by helping the kidneys remove excess glucose and sodium, which in turn reduces blood volume and pressure, easing the burden on the heart. Additionally, gene therapy is gaining attention as a potential future treatment for heart failure. Researchers are exploring how modifying certain genes could repair or regenerate damaged heart tissue, offering a long-term solution rather than just symptom management. Another exciting area of innovation is the development of novel biologics and cell-based therapies that could potentially reverse heart damage by promoting the regeneration of healthy heart tissue. Clinical trials are ongoing to test the efficacy of these advanced therapies, which could represent a significant breakthrough in how heart failure is treated in the coming decades. These developments, along with ongoing improvements in existing drug formulations, are continuously refining heart failure treatment strategies, offering patients more personalized and effective options.

What Are the Key Growth Drivers in the Heart Failure Drugs Market?

The growth in the heart failure drugs market is driven by several factors directly related to advancements in medical science, shifting demographics, and changing patient needs. One of the most significant factors is the rising prevalence of heart failure, driven by an aging population and the increasing incidence of cardiovascular diseases such as hypertension, diabetes, and coronary artery disease, which are major risk factors for heart failure. As the global population ages and chronic conditions become more prevalent, the demand for effective heart failure treatments continues to rise. In addition, advances in drug discovery and pharmaceutical technology have led to the development of new, more effective medications like SGLT2 inhibitors and ARNIs, which are transforming the standard of care and expanding the market for heart failure drugs. Furthermore, there is a growing focus on improving quality of life for heart failure patients, particularly in advanced cases, where new drug therapies aim to reduce hospital readmissions and manage symptoms more effectively. Another key driver is the increasing awareness and early diagnosis of heart failure, facilitated by better diagnostic tools and screening programs, leading to earlier intervention and more sustained use of medications. Moreover, the pharmaceutical industry’s shift toward personalized medicine, where treatments are tailored to the individual patient based on genetic, clinical, and lifestyle factors, is also expanding the market. These personalized approaches enable more effective management of heart failure, further driving demand for innovative and targeted therapies. Finally, the significant investment in research and development by both public and private sectors ensures a continuous pipeline of new treatments, fueling the growth of the heart failure drugs market as new, more effective solutions are brought to market.

SCOPE OF STUDY:

The report analyzes the Heart Failure Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Segment (Heart Failure Drugs)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 11 Featured) -

  • AstraZeneca PLC
  • Bayer AG
  • Boehringer Ingelheim (Canada) Ltd.
  • Bristol-Myers Squibb Company
  • CRC Health
  • Exelixis, Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Lunan Pharmaceuticals Co. Ltd.
  • Merck & Co., Inc.
  • Mylan N.V.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi S.A.
  • Shanghai Haini Pharmaceutical Co., Ltd.
  • Shanghai Xudong Haipu Pharmaceutical Co., Ltd.
  • The National Council for Palliative Care
  • Valeant Pharmaceuticals International, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Heart Failure Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Cardiovascular Diseases Propels Growth of the Heart Failure Drugs Market
    • Increasing Aging Population Expands Demand for Effective Heart Failure Treatments
    • Advancements in Drug Delivery Systems Spur Innovation in Heart Failure Drug Formulations
    • Growing Focus on Personalized Medicine Strengthens the Business Case for Targeted Heart Failure Therapies
    • Development of Novel Drug Classes Such as SGLT2 Inhibitors Drives Market Expansion
    • Rising Healthcare Expenditure and Access to Advanced Treatments Generate Opportunities in Emerging Markets
    • Increasing Adoption of Combination Therapies Strengthens Market Growth for Heart Failure Drugs
    • Surge in Demand for Oral Drugs and Non-Invasive Treatments Expands the Addressable Market
    • Growing Focus on Reducing Hospital Readmissions Drives the Need for Effective Long-Term Heart Failure Therapies
    • Expanding Use of Biomarkers for Disease Monitoring Enhances Adoption of Tailored Drug Regimens
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Heart Failure Drugs Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Heart Failure Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Heart Failure Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 5: USA Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 6: USA Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • CANADA
    • TABLE 7: Canada Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 8: Canada Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • JAPAN
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 9: Japan Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 10: Japan Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • CHINA
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 11: China Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 12: China Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • EUROPE
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 13: Europe Recent Past, Current & Future Analysis for Heart Failure Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 14: Europe Historic Review for Heart Failure Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 15: Europe 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • FRANCE
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 16: France Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 17: France Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • GERMANY
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 18: Germany Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Germany Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • ITALY
    • TABLE 20: Italy Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Italy Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • UNITED KINGDOM
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 22: UK Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: UK Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • SPAIN
    • TABLE 24: Spain Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Spain Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • RUSSIA
    • TABLE 26: Russia Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Russia Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • REST OF EUROPE
    • TABLE 28: Rest of Europe Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Rest of Europe Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • ASIA-PACIFIC
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 30: Asia-Pacific Recent Past, Current & Future Analysis for Heart Failure Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: Asia-Pacific Historic Review for Heart Failure Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 32: Asia-Pacific 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • AUSTRALIA
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 33: Australia Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 34: Australia Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • INDIA
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 35: India Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: India Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • SOUTH KOREA
    • TABLE 37: South Korea Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 38: South Korea Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • REST OF ASIA-PACIFIC
    • TABLE 39: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 40: Rest of Asia-Pacific Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • LATIN AMERICA
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 41: Latin America Recent Past, Current & Future Analysis for Heart Failure Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: Latin America Historic Review for Heart Failure Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Latin America 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 44: Argentina Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Argentina Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • BRAZIL
    • TABLE 46: Brazil Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Brazil Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • MEXICO
    • TABLE 48: Mexico Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Mexico Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • REST OF LATIN AMERICA
    • TABLE 50: Rest of Latin America Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Rest of Latin America Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • MIDDLE EAST
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 52: Middle East Recent Past, Current & Future Analysis for Heart Failure Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 53: Middle East Historic Review for Heart Failure Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 54: Middle East 15-Year Perspective for Heart Failure Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • IRAN
    • TABLE 55: Iran Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 56: Iran Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • ISRAEL
    • TABLE 57: Israel Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 58: Israel Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • SAUDI ARABIA
    • TABLE 59: Saudi Arabia Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Saudi Arabia Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • UNITED ARAB EMIRATES
    • TABLE 61: UAE Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 62: UAE Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • REST OF MIDDLE EAST
    • TABLE 63: Rest of Middle East Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 64: Rest of Middle East Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • AFRICA
    • Heart Failure Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 65: Africa Recent Past, Current & Future Analysis for Heart Failure Drugs by Segment - Heart Failure Drugs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Africa Historic Review for Heart Failure Drugs by Segment - Heart Failure Drugs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR

IV. COMPETITION